This article was originally published in The Gray Sheet
First application of a proprietary transvenous lead with a dual chamber pacemaker/implantable cardioverter defibrillator for treatment of congestive heart failure will occur "by the end of this month or for sure early in this quarter," company President and CEO Ron Dollens tells investors at the Hambrecht & Quist conference Jan. 11. "We think we know how to get to a location in the left ventricle that will give us optimal outcome and one will be able to discriminate the difference in that outcome," he notes. Separately, Dollens addresses Wall Street concern over potential pricing pressure in the U.S. coronary stent market. "What we do know about price is there has been some slight erosion in the U.S. market and we would represent that it declined 1% sequentially in the fourth quarter from the third quarter, so it does seem to be holding relatively nicely." He notes that average selling prices for stents advanced 11% during 1998
You may also be interested in...
Target guests in selected locations will be able to shop a curated Ulta Beauty section in the second half of 2021. The partnership could attract new clientele to Target stores and give Ulta a boost following nationwide store closures this year due to COVID.
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.